ChinaBio Partnering Forum 2022
Event summary
ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China which may now be viewed on demand. The event enabled delegates to identify, meet and engage with leaders across the life science value chain from global pharma and biotech companies to innovative startups and researchers from leading universities and institutes, as well as VCs and other investors. Cooley hosted a half-day bootcamp with two live virtual workshops on the first day of the forum.
View event details and watch sessions on demand
For more information, please email Sandra Sun.
Featured agenda items
Tuesday, November 8, 2022 | 14:00-15:00 CST
Partnering Bootcamp Session One: The Investors' Perspectives and Advice on Cross-Border Transactions
China-based life sciences companies, especially those with innovative assets and outstanding capabilities, have increasingly become a force to be reckoned with in the world of cross-border dealmaking. What is it like to be sitting across the negotiation table from foreign or multinational companies today? A panel of veteran investors offered their perspectives, and shared decades of insights, on a range of topics relevant to companies seeking to strike a licensing, collaboration, investment, joint venture, or M&A deal.
Speakers:
- Yiming Liu – Partner, Shanghai, Cooley (moderator)
- Fei Chen – Managing Partner, Lilly Asia Ventures
- Albert Huang – Managing Director, Yunfeng Capital
- Will Liu – Managing Director, BeiGene BioVentures
- Lynn Yang – Partner, Sequoia China
Tuesday, November 8, 2022 | 15:30-16:30 CST
Partnering Bootcamp Session Two: Down Market – What to Do in the New Economy
We may be entering a sustained down environment for the first time since 2008-2009. Many founders, investors and even lawyers have never experienced this, and even for those who have, it’s been a long time since you had to think about this. A group of panelists shared their perspectives on a series of related topics including tough terms in down environment financing, down rounds and anti-dilution, board and fiduciary duty, convertible loans and financing fallout and sales and restructuring.
Speakers:
- Michael Shen – Counsel, Shanghai, Cooley (moderator)
- John Jin – Co-founder, CFO/CBO, D3Bio, Inc.
- Sam Lou – President & COO, Hope Medicine Inc.
- Jun Mao – Chairman & Founder, Viva Ventures Biotech Fund
- Cheng Xing – Managing Partner, Sherpa Healthcare Partners
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.